Verona Pharma plc
PDMR Dealing
May 29, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, announces that, on May 28, 2019, Kayt Morgan, spouse of Mr. Piers Morgan, CFO of the Company, purchased 33,802 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 59 pence per Ordinary Share and a total purchase price of £19,954.18. Following the acquisition, Mr. Morgan will have a beneficial interest in the Company of 147,009 Ordinary Shares, representing 0.14% of the Company's issued share capital.
This purchase brings the total purchases by Mr. and Mrs. Morgan during the past few months to over £52,000 and follows the purchases made by the Company's Chairman, Dr. David Ebsworth, in March totaling approximately £50,000.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1 |
Details of the person discharging managerial responsibilities/person closely associated |
a) |
Name |
Kayt Morgan |
2 |
Reason for the notification |
a)
|
Position/status
|
Spouse (PCA) of Piers Morgan, Chief Financial Officer |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Verona Pharma plc |
b) |
LEI |
213800EVI6O6J3TIAL06 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 5 pence each GB00BYW2KH80 |
b) |
Nature of the transaction |
Purchase of Ordinary Shares |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
59 pence per Ordinary Share |
33,802 Ordinary Shares |
|
d) |
Aggregated information - Aggregated volume - Price |
N/A |
e) |
Date of the transaction |
28 May 2019 |
f) |
Place of the transaction |
London Stock Exchange, AIM |
For further information, please contact:
Verona Pharma plc |
Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer Victoria Stewart, Director of Communications |
[email protected] |
|
|
N+1 Singer (Nominated Adviser and UK Broker) |
Tel: +44 (0)20 3283 4200 |
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance) Mia Gardner (Corporate Broking) |
|